High Frequency Imaging in Cerebral Amyloid Angiopathy

Cerebral Amyloid Angiopathy Clinical Trial

— HIFI-CAA  

Official title:

High Frequency Imaging in Patients With Cerebral Amyloid Angiopathy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06128824
• Other study ID #: HIFI-CAA-01
• Status: Recruiting
• Start date: March 19, 2019
• Est. completion date: March 31, 2026

Study information

• Verified date: November 2023
• Source: Ludwig-Maximilians - University of Munich
• Contact: Martin Dichgans, MD
• Phone: +49 89 4400
• Email: martin.dichgans[@]med.uni-muenchen.de
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Cerebral amyloid angiopathy (CAA), caused by amyloid beta depositions in the walls of small cerebral vessels, is remarkably common in the elderly. Its major clinical consequences include intracerebral hemorrhages (ICH) typically in lobar location, functional dependence (disability) and cognitive impairment.

Cortical superficial siderosis (cSS) is a common finding in CAA patients and can even be the only magnetic resonance imaging sign of CAA. cSS is of high prognostic relevance regarding future intracerebral haemorrhage and disability. Previous studies suggest that cSS is caused by recurrent focal subarachnoid hemorrhages (fSAH). However, the exact mechanisms and the temporal dynamics of this highly relevant imaging finding are largely unknown.

In addition to hemorrhagic manifestations, such as cSS, CAA patients also show ischemic lesions. Of particular interest are acute ischemic lesions as detected by diffusion imaging, which seem to be highly prevalent. Since haemorrhagic and ischemic lesions require fundamentally different therapeutic strategies, understanding the relevance and interplay of both lesion types is highly important for clinical decision making.

The HIFI-CAA cohort study aims to provide novel insights into cSS, acute ischemic lesions and other relevant brain alterations in CAA through high-frequency (monthly) serial magnetic resonance imaging.

Description:

Cerebral amyloid angiopathy (CAA) is defined as the deposition of β-amyloid in the walls of small cortical cerebral vessels. It is very common in the elderly population with prevalence rates up to 60% and is associated with Alzheimer´s disease. Intracerebral lobar macrohemorrhages (ICH) are the most devastating presentation of CAA and the main cause of morbidity and mortality. In addition to developing clinically manifest strokes, CAA patients may also suffer from transient neurological symptoms and progressive cognitive impairment ultimately resulting in dementia.

Apart from ICH, typical MRI signs of CAA include multiple cerebral microbleeds (CMB) in a cortical-subcortical localization, white matter hyperintensities on T2-weighted images and supratentorial cortical superficial siderosis (cSS). Main risk factors for recurrence of CAA-related ICH are apolipoprotein E ε2 or ε4 alleles, previous ICHs and CMB on follow-up imaging. Recently, cSS emerged as an additional, major independent risk factor for ICH and disability.

In CAA, siderosis affects the convexity of the cerebral hemispheres, and thus is termed cortical superficial siderosis (cSS). This is in contrast to infratentorial superficial siderosis, which is not linked to CAA. CSS is likely caused by recurrent non-traumatic, focal convexity subarachnoid hemorrhages (fSAH). There are causes of fSAH and cSS other than CAA, and these causes seem to vary depending on age: in younger patients (< 60 years of age) fSAH and cSS are most commonly seen in the context of trauma, vasculitis and reversible cerebral vasoconstriction syndrome, while CAA seems to be the by far most common cause in subjects above 60 years of age. cSS is common (> 60%) in patients with histologically proven CAA, and may be the only hemorrhagic imaging sign on MRI.

Lesions on diffusion-weighted imaging, i.e. areas of restricted diffusion, are a very frequent finding in CAA. These diffusion restrictions can be found in 25% to 50% of CAA patients when performing a single MRI. One recent study even suggests a spatial relationship with cSS. The clinical significance of these lesions is not yet fully established. The most likely pathophysiology behind these lesions is acute ischemia, or to be more precise cytotoxic edema after brain ischemia/infarction. However, subcortical infarcts as detected through a diffusion-restricted lesion can have vastly different fates, ranging from disappearance to complete brain tissue loss (cavitation). An important step in the understanding of these lesions is the precise estimation of prevalence and tissue consequences. A critical point in this endeavour is that these diffusion restricted lesions are typically only visible for a few weeks. Thus, they can remain completely undetected in studies using conventional study designs with follow-up intervals as long as 6 months, one year or even longer.

While small subcortical and cortical ischemic lesions (detectable as diffusion restrictions) are a common finding in CAA patients, their exact prevalence and relevance for disease progression are unclear. Overall, temporal dynamics of the processes leading to hemorrhagic and ischemic manifestations of CAA as well as their interrelationships are insufficiently understood. These critical aspects can be addressed by a novel study design with serial, monthly magnetic resonance imaging. The study design is inspired by a recent high-frequency serial imaging study in patients with sporadic, non-amyloid cerebral small vessel disease conducted at Nijmegen (Radboud University Nijmegen Diffusion tensor and Magnetic resonance imaging Cohort - Investigating The origin and Evolution of cerebral small vessel disease, RUN DMC - InTENse).

The primary aim of this study is to prospectively evaluate the development and temporal evolution of incident and prevalent fSAH & cSS in CAA patients.

Secondary aims are i) to assess the monthly incidence of acute ischemic lesions (diffusion restrictions) in CAA patients with cSS/fSAH and to compare the incidence with lobar ICH survivors, and ii) to assess the inter-relationship between hemorrhagic lesions (fSAH/cSS/CMB) and acute ischemic lesions as well as the association between these lesions and cerebrovascular event rates and functional status.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 75
• Est. completion date: March 31, 2026
• Est. primary completion date: March 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years and older

Eligibility

Inclusion Criteria:

• Probable CAA according to the modified Boston criteria with evidence of

1. cSS or fSAH

2. lobar ICH survivors without cSS or fSAH

• Absence of ICH or microbleed in deep locations (basal ganglia, thalamus, brain stem)

• Absence of infratentorial siderosis or infratentorial SAH

• MR-/CT-/DS-angiography without evidence of cerebral aneurysm, AVM, AV-fistula or other possible etiology for the observed haemorrhagic manifestations

• No history of head trauma resulting in loss of consciousness or radiologically visible traumatic brain injury

• Written informed consent by patient herself/himself prior to study enrolment

Exclusion Criteria:

• Unwillingness to participate in high-frequency (monthly) follow-up

• Severe medical condition with expected life expectancy <1 year

• Contraindications for MRI (following local guidelines of the respective study center)

Related Conditions & MeSH terms

• Amyloidosis
• Cerebral Amyloid Angiopathy

Intervention

Other:
• MR Imaging
Serial magnetic resonance imaging (MRI)

Locations

Country	Name	City	State
Germany	DZNE/Bonn - Klinik und Poliklinik für Neurologie, Universitätsklinikum Bonn	Bonn
Germany	DZNE/Magdeburg - Universitätsklinikum Magdeburg	Magdeburg
Germany	Insitute for Stroke and Dementia Research	Munich

Sponsors (1)

Lead Sponsor	Collaborator
Martin Dichgans

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	new hemorrhagic features as determined by heme-sensitive MRI	new hemorrhagic features (e.g., cSS) as determined by heme-sensitive magnetic resonance imaging such as T2*-weighted gradient echo (GRE) and susceptibility weighted imaging (SWI)	monthly up to 12 months
Secondary	DWI+ lesions on diffusion weighted imaging MRI	DWI+ lesions on diffusion weighted imaging (DWI) on magnetic resonance imaging	monthly up to 12 months
Secondary	modified Rankin Scale	functional outcome on modified Rankin Scale (score [0-6] with higher scores meaning a worse outcome)	monthly up to 12 months
Secondary	neuropsychological evaluation (global cognition using MoCA)	neuropsychological evaluation of cognition using the Montreal Cognitive Assessment (MoCA) (score [0-30] with higher scores meaning a better outcome)	baseline and after 12 months
Secondary	neuropsychological evaluation (global cognition using MMSE)	neuropsychological evaluation of cognition using the Mini Mental State Examination (MMSE) (score [0-30] with higher scores meaning a better outcome)	baseline and after 12 months
Secondary	neuropsychological evaluation (processing speed and executive function)	neuropsychological evaluation of processing speed and executive function using the Trail Making Test (TMT) A and TMT B measuring the time in seconds to complete the task; age- and education-corrected z-scores will be derived	baseline and after 12 months
Secondary	reaction time (attention)	reaction time assessed with Test of Attentional Performance (TAP) test	monthly up to 12 months